| |
Tuesday, October 11, 2022 | 2pm ET / 11am PT Drug rebates are complex and the subject of legislative influence, creating a uniquely challenging ecosystem where gaps in knowledge, data and technology can create challenges. Register now to learn how manufacturers can respond quickly to changes in policies. 
|
|
| By Helen Floersh Scientists have identified a new set of non-opioid molecules that ease pain without sedation. Their hope is that the drugs can be used alongside opioids, lowering the dose needed for relief. |
|
|
|
By Fraiser Kansteiner Wednesday, the U.S. Department of Health and Human Services (HHS) said it’s throwing down $290 million to lock up an undisclosed amount of Amgen’s blood disorder med Nplate, which is approved to treat blood cell injuries linked to acute radiation syndrome (ARS) in kids and adults. |
By Nick Paul Taylor AstraZeneca has identified a shortcut to prominence in the genomic medicine space. Working through its Alexion rare disease unit, the Big Pharma has struck a deal to snap up struggling LogicBio Therapeutics to secure technology platforms and expertise in their use. |
By Kevin Dunleavy Amid reports that AstraZeneca's Evusheld is ineffective against the latest subvariant of omicron, BA.4.6, the FDA has updated its fact sheet for the antibody combo. The agency now says the product can increase the risk of COVID-19 infection for variants that it does not neutralize. |
By Conor Hale The agency’s green light expands the company’s AIR Recon DL programs from 2D to 3D imaging sequences, eliminating the need to take multiple 2D scans to reach a diagnosis in certain cases. |
By Angus Liu Merck’s Keytruda is well established as the standard treatment for newly diagnosed metastatic non-small cell lung cancer. For PD-1 latecomer Jemperli from GSK, an impressive trial showing met the tough bar established by the Merck blockbuster. |
By Gabrielle Masson Bristol Myers Squibb is partnering up with San Francisco biotech SyntheX to ride into the lawless land of molecular glue degrader discovery—all while giving the biotech the potential to pocket up to $550 million in biobucks. |
By Fraiser Kansteiner After an indefinite commercial delay on its Shire-acquired rare disease drug this spring, Takeda’s yearslong Natpara manufacturing saga is drawing to a close. |
By Ben Adams As it awaits FDA approval for its Demodex blepharitis drug, Tarsus is wasting no time in getting awareness of this little-known eye disease out into the public domain. |
By Gabrielle Masson As the cell and gene field builds off a quarter of great scientific progress, the industry may be teetering on the brink of transforming medicine as we know it. |
Fierce podcasts Don't miss an episode |
| This week on "The Top Line," we talk about trial results for Eisai and Biogen's Alzheimer’s drug, which were surprisingly good, and we dig into what comes next. We also discuss how Pfizer is ramping up its DTC ad campaign for its COVID shots, most recently spending big on a booster ad for the NFL season. |
|
|---|
|
|
|
Monday, October 17, 2022 | 11am ET / 8am PT Join the Omic Revolution! Register now to attend a FREE webinar to leverage deep multiomic data integration for target and biomarker discovery. 
|
|
eBook In this free guide, explore how Cloud Computing is enabling emerging biopharma organizations to decrease time-to-discovery in pursuit of breakthrough treatment modalities. Sponsored by: RCH Solutions |
Whitepaper Learn the benefits of unlocking data insights across the healthcare and life sciences ecosystem. Sponsored by: NTT Data |
Whitepaper This paper is the first in a 4-part series focused on developing commercial models for gene therapies Sponsored by: Blue Matter, strategic consultants in the life sciences |
eBook With real-world data playing a significant role in health care decisions, life sciences leaders need to maximize their data investments. The best place to start is right here, with our e-book on the four steps to a more coordinated, connected real-world data strategy. Sponsored by: Optum |
Whitepaper SaaS LIMS from LabVantage Solutions Is Pre-Validated for Regulated Industries, Delivering Maximum Flexibility, Uptime, and Security. Sponsored by: LabVantage Solutions Inc. |
eBook Improve your congress competitive intelligence and cut down costs by 50% Sponsored by: Ferma.AI, a Product of ZoomRx |
Whitepaper Advanced research requires advanced tools. The next-generation ELISA takes a fraction of the time to run eight analytes simultaneously while saving your sample volume. Sponsored by: Bio-Techne |
eBook Improve patient engagement, adherence, and outcomes Sponsored by: Health Catalyst |
Whitepaper Supporting your product development programme through experience, expertise, and efficiency. Sponsored by: Almac Pharma Services |
Video Can an optimized research process--including AI-powered workflow and process automation tools--help get breakthrough drugs to market faster? Sponsored by: Proscia |
Video Learn how a centralized platform for pathology images, metadata, and analysis results can connect previously siloed research initiatives and advance our collective understanding of tissue. Sponsored by: Proscia |
Whitepaper What is the most suitable dosage form technology for the Oral Delivery of Lipid-Based Formulations? Sponsored by: Catalent |
Research Learn more about how the versatility of Softgel Technology helped a customer with a volatile compound. Sponsored by: Catalent |
Whitepaper How can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market? Sponsored by: Catalent |
Whitepaper Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Sponsored by: Catalent Biologics |
Webinar Ypsomed and Catalent Biologics experts discuss strategies for integrated PFS manufacturing and auto-injector assembly to accelerate timelines and more in this webinar. Sponsored by: Catalent Biologics |
Custom Resource Center Read through this library of resources to find out how you can strengthen innovation and efficiency, improve safety and quality, and prioritize resources to support your long-term goals. Sponsored by: JLL |
Whitepaper Clarus Therapeutics (Clarus) is a men’s specialty pharmaceutical company that partnered with Catalent to develop a unique and convenient drug delivery form for their hormone replacement therapy. Sponsored by: Catalent |
Whitepaper Learn more about how the transition from early to late phase of a small molecule program plays a pivotal role in a program’s ultimate success. Sponsored by: Catalent |
Whitepaper Explore how Thermo Scientific’s Process Liquid Preparation Services can help you plan for scalable buffer preparation. Sponsored by: Thermo Fisher Scientific |
| |
|
